New hope for heart patients: drugs target hidden inflammation from blood mutations

NCT ID NCT06097663

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two experimental drugs, DFV890 (a daily pill) and MAS825 (a single shot), in 31 adults with coronary heart disease and a blood condition called CHIP. The goal was to see if these drugs could reduce specific markers of inflammation linked to heart risk. The trial was completed and focused on safety and how well the drugs lowered inflammation levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clonal hematopoiesis of indeterminate potential coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) CORONARY HEART DISEASE

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Montreal, Quebec, H1T 1C8, Canada
Novartis Investigative Site

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site

Bonn, 53105, Germany
Novartis Investigative Site

München, 80636, Germany
Vanderbilt University Medical Cent

Nashville, Tennessee, 37232-8805, United States
Washington University

St Louis, Missouri, 63110, United States